Patients recruited for pancreatic cancer screening study.
"Much of our understanding of the genetics on the development of sporadic colorectal cancer stems from our understanding of familial colorectal cancer," said Dr. Canto, director of clinical research in the division of gastroenterology and hepatology at the Johns Hopkins University, Baltimore.
"Maybe we're 10 years behind in fully understanding the genetics of pancreatic cancer, but hopefully we'll get there." Since pancreatic cancer in relatives tends to develop in the 60s, Dr. Canto recommends that family members be screened starting at age 40 years, or 10 years younger than the youngest relative with the disease.
"Clearly, known family history is a risk factor," she said. "Screening can detect asymptomatic treatable neoplasms, as well as pancreatic neoplasms and extra-pancreatic neoplasms."
In patients with Peutz-Jeghers syndrome, pancreatic cancer tends to present in the fourth decade of life. "Therefore, we propose that perhaps you would [screen these patients] at an earlier age, maybe at age 30," she said. "We don't know for sure."
In addition, smoking increases the risk and lowers age of onset by 10 years in people with a family history of the disease. "The first thing you can do for your patients besides taking a family history is tell them to stop smoking," she said.
Intraductal papillary mucinous neoplasm, multifocal pancreatic intraepithelial neoplasia, and lobulocentric chronic pancreatitis are part of the phenotype of familial pancreatic cancer. The best screening tests remain unknown, but various studies have suggested a role for endoscopic ultrasound (EUS), computed tomography (CT), magnetic resonance imaging (MRI), combined EUS/fine-needle aspiration, and endoscopic retrograde cholangiopancreatography.
In an effort to determine the optimal screening methods, Dr. Canto and her associates are currently recruiting patients for The Lustgarten Foundation for Pancreatic Cancer Research-National Cancer Institute Specialized Programs of Research Excellence Cancer of the Pancreas Screening Study (CAPS 3).
The researchers plan to screen high-risk individuals for early pancreatic neoplasia using EUS, CT, and MRI/magnetic resonance cholangiopancreatography (MRCP), and test a panel of candidate biomarkers.
They hypothesize that screening tests can detect early curable noninvasive pancreatic neoplasia in high-risk individuals before it progresses to invasive cancer.
Patients eligible for enrollment in the investigation include:
* Adults with at least two first-degree relatives (parent, sibling, child) with pancreatic cancer. If the family has three or more relatives with the disease, then the individual must have at least one first-degree relative affected; if the family has two relatives with pancreatic cancer, then the individual must have two first-degree relatives affected.
* Adults with Peutz-Jeghers syndrome.
* Adults who are carriers of the BRCA2 or familial atypical multiple mole melanoma (FAMMM) p16(CDKN2A) gene and there is at least one family member who had pancreatic cancer.
For additional questions about patient enrollment, contact firstname.lastname@example.org.
San Diego Bureau
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Digestive Disorders|
|Publication:||Family Practice News|
|Date:||Mar 1, 2007|
|Previous Article:||Virtual, optical colonoscopy are alike, study says.|
|Next Article:||Barrett's guidelines lack support in practice.|